Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Business

Oxford Brain Diagnostics to roll out revolutionary dementia technology following UK and US regulatory approvals

by May 27, 2025
May 27, 2025
Oxford Brain Diagnostics to roll out revolutionary dementia technology following UK and US regulatory approvals

Oxford Brain Diagnostics (OBD) is preparing to launch its groundbreaking technology for the early diagnosis of dementia across the UK and US healthcare markets, following a wave of key regulatory approvals that mark a major milestone in the company’s growth.

Backed by growth capital investor BGF, the Oxford-based medtech firm will begin commercial deployment of its patented Cortical Disarray Measurement (CDM) software — a novel tool that can objectively measure neurodegeneration using standard MRI scans. By enabling earlier and more accurate assessments of brain health, the technology is poised to transform how conditions like Alzheimer’s are diagnosed and monitored.

The roll-out follows successful FDA 510(k) clearance and UKCA self-certification, which together provide the regulatory green light for entry into two of the world’s most significant healthcare markets. The company now aims to expand into hospitals, clinics and clinical research organisations that urgently need non-invasive, precision diagnostic tools.

“Neurodegenerative diseases represent a growing public health challenge,” said Dr Steven Chance, CEO and co-founder of OBD. “The support from BGF and our other partners has been instrumental in taking CDM from the lab to the clinic. We’re now in a position to bring hope to millions seeking clarity on their brain health.”

OBD was co-founded in 2019 by Dr Chance, a former Associate Professor of Neuroscience at Oxford University, and Professor Mark Jenkinson, an expert in neuroimaging. The CDM platform builds on decades of scientific research into the structural changes in the brain associated with Alzheimer’s and other neurodegenerative conditions.

The company gained early validation in 2020 when the US Food and Drug Administration (FDA) granted CDM Breakthrough Device Designation, recognising the tool’s potential in identifying early-stage Alzheimer’s in adults.

OBD’s commercial progress has been powered by a multi-million pound funding round in 2023, led by BGF, the UK and Ireland’s most active growth capital investor. Continued support also came from existing backers, including the Oxford Technology & Innovations Fund (OTIF).

“OBD’s progress over the past two years has been remarkable,” said Maggy Lau, investor at BGF. “The technology is truly differentiated, and its recent regulatory achievements show just how close it is to making a major impact. We’re proud to back a company tackling one of the most urgent and important challenges in healthcare today.”

The company has already begun forging strategic partnerships with pharmaceutical firms, helping to support clinical trials and drug development by offering a reliable and scalable method for evaluating patients. As new Alzheimer’s treatments emerge, demand for accurate diagnostic tools is expected to surge — a gap OBD is now well placed to fill.

While CDM’s initial focus is on Alzheimer’s, its broader applications are already being explored. Early studies show potential in diagnosing and tracking other neurodegenerative diseases, including Parkinson’s Disease and Multiple Sclerosis.

With global dementia cases expected to double every 20 years, the need for early and accurate diagnostics has never been more pressing. OBD’s breakthrough signals a shift in how brain health can be evaluated, tracked and ultimately treated, moving beyond symptoms to deliver data-driven, proactive care.

As the UK and US roll-outs begin, OBD’s platform could soon become a central tool in both clinical settings and pharmaceutical pipelines, offering a new lens through which neurodegeneration can be understood — and tackled.

Read more:
Oxford Brain Diagnostics to roll out revolutionary dementia technology following UK and US regulatory approvals

0
FacebookTwitterGoogle +Pinterest
previous post
Cambridge warns UK must scale up investment to turn spin-outs into global success stories
next post
UK and EU to deepen AI collaboration with launch of new UK ‘AI Factory Antenna’

You may also like

  From Exploration to Science: Innovative Technology and...

May 18, 2023

Addison Lee invests in the future of London’s...

February 8, 2024

UK’s energy supply needs over £900 billion investment...

December 7, 2023

Post Office awards new deal for IT system...

April 19, 2023

Amazon workers in Coventry make historic bid for...

April 26, 2023

Squeezed Homeowners Opt for Longer Mortgage Terms

April 14, 2024

Private Sector Expansion Bolsters UK Economic Outlook Despite...

February 6, 2024

Starling Bank fined £29m for ‘shockingly lax’ financial...

October 4, 2024

UK banks pull half of first-time buyer friendly...

October 25, 2022

Selfridges losses narrow amid further calls for return...

October 12, 2023

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Tariff “Inclusion” Process Comes with High Costs, Absurd Outcomes, and Extra Cronyism

      August 22, 2025
    • Trump DOJ releases ‘thousands’ of Epstein files to House Oversight Committee

      August 22, 2025
    • Jackson scathing dissent levels partisan charge at colleagues after high-profile ruling

      August 22, 2025
    • ‘Leftist’ taxpayer-funded academy sparks backlash after moving against Trump’s rollback of key regulation

      August 22, 2025
    • Friday Feature: Helena Homeschool Enrichment Co-op

      August 22, 2025
    • John Bolton blasted by Trump ally Roger Stone, who faced Biden FBI raid: ‘Karma is a b—-‘

      August 22, 2025

    Categories

    • Business (8,855)
    • Investing (2,235)
    • Politics (16,464)
    • Stocks (3,228)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved